Best Available Copy



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
050,083	06-19-7	9 Berntsson et al.	24,040

Brumbaugh, Graves, Donohue & Raymond 30 Rockefeller Plaza New York, N.Y. 10020

EXAMINER	
Alan L.Rot	tman
ART UNIT	PAPER NUMBER
121	3.
DATE MAILED:	MAILED

This is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

OCT 10 1979

This application has been examined.	Responsive to communication filed or	n	GROUP 120
A shortened statutory period for responding to respond within the period for	nse to this action is set to expire3 r response will cause the application to become		lays from the date of this letter.
Part I THE FOLLOWING ATTACHME 1. Notice of References Cited, I 3. Notice of Informal Patent Ap	· · · · · · · · · · · · · · · · · · ·	tice of Informal Patent D	erawing, PTO-948.
Part II SUMMARY OF ACTION 1. Claims			are pending in the application.
			_ are withdrawn from consideration.
2. Claims			_ have been cancelled.
3. Claims			_ are allowed.
4. Claims	1-11		_ are rejected.
5. Claims			are objected to.
6. Claims		are subject	to restriction or election requirement
7. The formal drawings filed on		are accepta	able.
8. The drawing correction requ	est filed on	has been	approved. disapproved.
· 🖵	the claim for priority under 35 U.S.C. 119. To been received.		
	filed on	•	
	s to be in condition for allowance except for f nder Ex parte Quayle, 1935 C.D. 11; 453 O.G		on as to the merits is closed in ac-
11. Other			

FORM	PTO-1142
(3 - 75)	

PART III

U. S. DEPARTMENT OF COMMERCE Patent and Trademark Office

SERIAL NUMBER 050,083

GROUP ART UNIT

NOTIFICATION OF REJECTION(S) AND/OR OBJECTION(S) (35 USC 132)

	CLAIMS	REASONS FOR REJECTION (2)	REFERENCES *	INFORMATION IDENTIFICATION AND COMMENTS (4)
1	1-11	35 U.S. 103		Claims 1-11 are rejected as being unpatent able over U.S.Patent No.3,488,359 which discloses compounds which generically include the claimed compounds, specifically discloses analogues of 1,4-dihydropyridine-3,5-dicarboxylates, same utility and pharmace ical preparations in column 3 which raises a presumption of obviousness.
2	1-11	35 U.S.C 103	• "B"	Claims 1-11 are rejected as being unpatentable over U.S.Patent 3,441,648 which discloses closely related I,4-dihydro-2,6-dimethyl-4-substituted aryl-3,5-pyridinedicarboxylates, same utility and pharmaceutical preparations in column 8 which gives rise to a presumption of obviousness.
3	1-11	35 U.S.C 102 & 103	"C"	Claims 1-11 are rejected as being fully met by U.S.Patent No.3,799,936 which discloses a limited number of 1,4-dihydropyridines which clearly read on instant claims as well as same utility and pharmaceutical preparati in column6.Closely related analogues in addition raise a presumption of obviousness under 35 U.S.C.103.
4	5-7 8-11	35 U.S.C 112 sec.par. 35 U.S.C		Method claims should recite mode of administration and effective amount of active compound. Pharmaceutical composition claims
		sec.par.		propriety when composition alludes to one or more active compounds of a Markush group when support in spec. is for one only.

5	

* Capital letters representing references are identified on accompanying Form PTO-892.

The symbol "v" between letters represents - in view of -.

The symbol "+" or "&" between letters represents - and -.

A slash "/" between letters represents the alternative - or -.

NOTE: Sections 100, 101, 102, 103, and 112 of the Patent Statute (Title 35 of the United States Code) are reproduced on the back of this sheet. Alan L.Rotman

TEL. NO. (703) -557 -2517

Clan L. ROTMAN
EXAMINER
GROUP ART UNIT 121

73